Finch Therapeutics has just finished its Series C round of financing, raising $53m in the process.


Finch Therapeutics is a very interesting company specializing in using bacterial cultures to restore the natural balance of the bacterial colonies that populate our body (our microbiome) which diseases/drug therapies are able to disrupt.
The major player in Finch Therapeutics pipeline is its product CP10, an oral capsule that contains a diverse range of microbiota that can restore the bodies microbiome. At the moment it is currently being studied in Finch’s PRISM3 phase three clinical trial for the prevention of recurrent C.difficile infections. The company hopes that this money will help to push the trial towards pivotal results.

Earlier this year Finch Therapeutics secured a breakthrough therapy designation (BTD) from the FDA for CP10. This is huge news for Finch as it would mean that the FDA could help push CP10 ahead of other microbiota rivals.

The company also plans to use this new founded financing for its development programme for a treatment for Autism Spectrum Disorder (ASD). With the biotech firm currently evaluating the safety and efficacy of its product in a Stage 2 trial. Finch has a focus on ASD because sufferers often experience behavioral problems that are interlinked with gastrointestinal symptoms, with previous studies suggesting a link between the two symptoms.

Finch Therapeutics is not the only company seeing promise in the microbiota sector, with rival company Rebiotix presenting early data in 2017 that its microbiota suspension RBX2660 prevents recurrences of C.difficile infections. With Rebiotix currently enrolling patients in a phase three clinical trial to also study the safety and efficacy of its trial.

The microbiome sector has not gone unnoticed by big pharma with large companies spending big investments. In March this year, AstraZeneca paid US biotech Seres Therapeutics in $20m in instalments over the next two years, with reimbursements, to explore how the bacteria in the gut can affect and enhance cancer immunotherapies. And last June, Roche’s biotech subsidiary Genentech signed a $534m deal with UK biotech Microbiota to access its precision metagenomics microbiome platform to analyse samples of its clinical data for investigational IBD medicines.

No comments:

Post a Comment

Coranavirus and its relationship with IP exclusivity

With the global shutdown that has occurred due to COVID-19, its presence has caused long-lasting effects in all aspects of our lives and t...